Group Leader
José Antonio Ramos-Quiroga
Principal Investigator (PI)
Anna Beneria González, Mª Dolores Braquehais Conesa, Eugeni Bruguera Cortada, Natalia Calvo Piñero, Francisco Collazos Sanchez, Marc Ferrer Vinardell, Sara Guila Fidel Kinori, Núria Gómez Barros, Lara Grau Lopez, Carlos Jacas Escarcellé, Pilar Lusilla Palacios, José Antonio Navarro Sanchís, Gemma Parramon Puig, Marta Quesada Franco, Vanesa Richarte Fernández, Amanda Rodríguez Urrutia, María Soler, Christian Fadeuilhe, Laura Gisbert
Researchers
Silvia Alemany Sierra, Dimitra Tatiana Anastasiadou, Mª Sonsoles Cepeda Diez, , Raquel Vidal Estrada, Silvia Amoretti, Jorge Lugo Marin, Gemma Nieva Rifa, Gabriela Perez Fuentes Ruiz, Elena Ros, Constanza Daigré, Montserrat Corrales, Gara Arteaga Henriquez
PhD Students
Mireia Forner Puntonet, Christina Regales Peco, Miguel Angel Sandonis Vicente, Oscar Soto Angona, Laura Vilar Ribo, Pedro Serrano Pérez, Felipe Palma, Gemma Español, Natàlia Llonga
Lab Technicians
Lorena Arribas Garcia
Nursing and Technical Staff
Montserrat Fabregat Garcia, Pol Ibañez Jimenez, Estela García Egea, Judit Palacio Sanchez, Carolina Ramos Sayalero, Imanol Setien Ramos, Silvia Muñoz, Àlex Rué Jiménez, Berta Roig, MªFernanda Sousa, Raquel Ibarz López
59
PUBLICATIONS
50.8%
%Q1
407
IMPACT FACTOR
6.89
AVERAGE IMPACT FACTOR
SELECTED ARTICLES
Rajagopal VM, Duan J, Vilar-Ribó L, Grove J, Zayats T, Ramos-Quiroga JA, Satterstrom FK, Artigas MS, Bybjerg-Grauholm J, Bækvad-Hansen M, Als TD, Rosengren A, Daly MJ, Neale BM, Nordentoft M, Werge T, Mors O, Hougaard DM, Mortensen PB, Ribasés M, Børglum AD, Demontis D.
Differences in the genetic architecture of common and rare variants in childhood, persistent and late- diagnosed attention-deficit hyperactivity disorder
Nat Genet. 2022 Aug;54(8):1117-1124.
DOI: doi: 10.1038/s41588-022-01143-7
IF: 41.376
Sforzini L, Worrell C, Kose M, Anderson IM, Aouizerate B, Arolt V, Bauer M, Baune BT, Blier P, Cleare AJ, Cowen PJ, Dinan TG, Fagiolini A, Ferrier IN, Hegerl U, Krystal AD, Leboyer M, McAllister-Williams RH, McIntyre RS, Meyer-Lindenberg A, Miller AH, Nemeroff CB, Normann C, Nutt D, Pallanti S, Pani L, Penninx BWJH, Schatzberg AF, Shelton RC, Yatham LN, Young AH, Zahn R, Aislaitner G, Butlen-Ducuing F, Fletcher C, Haberkamp M, Laughren T, Mäntylä FL, Schruers K, Thomson A, Arteaga-Henríquez G, Benedetti F, Cash-Gibson L, Chae WR, De Smedt H, Gold SM, Hoogendijk WJG, Mondragón VJ, Maron E, Martynowicz J, Melloni E, Otte C, Perez-Fuentes G, Poletti S, Schmidt ME, van de Ketterij E, Woo K, Flossbach Y, Ramos-Quiroga JA, Savitz AJ, Pariante CM.
A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.
Mol Psychiatry. 2022 Mar;27(3):1286-1299.
DOI: doi: 10.1038/s41380-021-01381-x
IF: 13.437
Mullins N, Kang J, Campos AI, Coleman JRI, Edwards AC, Galfalvy H, Levey DF, Lori A, Shabalin A, Starnawska A, Su MH, Watson HJ, Adams M, Awasthi S, Gandal M, Hafferty JD, Hishimoto A, Kim M, Okazaki S, Otsuka I, Ripke S, Ware EB, Bergen AW, Berrettini WH, Bohus M, Brandt H, Chang X, Chen WJ, Chen HC, Crawford S, Crow S, DiBlasi E, Duriez P, Fernández-Aranda F, Fichter MM, Gallinger S, Glatt SJ, Gorwood P, Guo Y, Hakonarson H, Halmi KA, Hwu HG, Jain S, Jamain S, Jiménez-Murcia S, Johnson C, Kaplan AS, Kaye WH, Keel PK, Kennedy JL, Klump KL, Li D, Liao SC, Lieb K, Lilenfeld L, Liu CM, Magistretti PJ, Marshall CR, Mitchell JE, Monson ET, Myers RM, Pinto D, Powers A, Ramoz N, Roepke S, Rozanov V, Scherer SW, Schmahl C, Sokolowski M, Strober M, Thornton LM, Treasure J, Tsuang MT, Witt SH, Woodside DB, Yilmaz Z, Zillich L, Adolfsson R, Agartz I, Air TM, Alda M, Alfredsson L, Andreassen OA, Anjorin A, Appadurai V, Soler Artigas M, Van der Auwera S, Azevedo MH, Bass N, Bau CHD, Baune BT, Bellivier F, Berger K, Biernacka JM, Bigdeli TB, Binder EB, Boehnke M, Boks MP, Bosch R, Braff DL, Bryant R, Budde M, Byrne EM, Cahn W, Casas M, Castelao E, Cervilla JA, Chaumette B, Cichon S, Corvin A, Craddock N, Craig D, Degenhardt F, Djurovic S, Edenberg HJ, Fanous AH, Foo JC, Forstner AJ, Frye M, Fullerton JM, Gatt JM, Gejman PV, Giegling I, Grabe HJ, Green MJ, Grevet EH, Grigoroiu-Serbanescu M, Gutierrez B, Guzman-Parra J, Hamilton SP, Hamshere ML, Hartmann A, Hauser J, Heilmann-Heimbach S, Hoffmann P, Ising M, Jones I, Jones LA, Jonsson L, Kahn RS, Kelsoe JR, Kendler KS, Kloiber S, Koenen KC, Kogevinas M, Konte B, Krebs MO, Landén M, Lawrence J, Leboyer M, Lee PH, Levinson DF, Liao C, Lissowska J, Lucae S, Mayoral F, McElroy SL, McGrath P, McGuffin P, McQuillin A, Medland SE, Mehta D, Melle I, Milaneschi Y, Mitchell PB, Molina E, Morken G, Mortensen PB, Müller-Myhsok B, Nievergelt C, Nimgaonkar V, Nöthen MM, O'Donovan MC, Ophoff RA, Owen MJ, Pato C, Pato MT, Penninx BWJH, Pimm J, Pistis G, Potash JB, Power RA, Preisig M, Quested D, Ramos-Quiroga JA, Reif A, Ribasés M, Richarte V, Rietschel M, Rivera M, Roberts A, Roberts G, Rouleau GA, Rovaris DL, Rujescu D, Sánchez-Mora C, Sanders AR, Schofield PR, Schulze TG, Scott LJ, Serretti A, Shi J, Shyn SI, Sirignano L, Sklar P, Smeland OB, Smoller JW, Sonuga-Barke EJS, Spalletta G, Strauss JS, Świątkowska B, Trzaskowski M, Turecki G, Vilar-Ribó L, Vincent JB, Völzke H, Walters JTR, Shannon Weickert C, Weickert TW, Weissman MM, Williams LM, Wray NR, Zai CC, Ashley-Koch AE, Beckham JC, Hauser ER, Hauser MA, Kimbrel NA, Lindquist JH, McMahon B, Oslin DW, Qin X; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium; Bipolar Disorder Working Group of the Psychiatric Genomics Consortium; Eating Disorders Working Group of the Psychiatric Genomics Consortium; German Borderline Genomics Consortium; MVP Suicide Exemplar Workgroup; VA Million Veteran Program; Agerbo E, Børglum AD, Breen G, Erlangsen A, Esko T, Gelernter J, Hougaard DM, Kessler RC, Kranzler HR, Li QS, Martin NG, McIntosh AM, Mors O, Nordentoft M, Olsen CM, Porteous D, Ursano RJ, Wasserman D, Werge T, Whiteman DC, Bulik CM, Coon H, Demontis D, Docherty AR, Kuo PH, Lewis CM, Mann JJ, Rentería ME, Smith DJ, Stahl EA, Stein MB, Streit F, Willour V, Ruderfer DM.
Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors.
Biol Psychiatry. 2022 Feb 1;91(3):313-327.
DOI: doi: 10.1016/j.biopsych.2021.05.029
IF: 12.81
Fadeuilhe C, Daigre C, Grau-López L, Richarte V, Palma-Álvarez RF, Corrales M, Sáez B, Baz M, Ramos-Quiroga JA.
The impact of insomnia disorder on adult attention-deficit/hyperactivity disorder severity: A six-month follow-up study.
Psychiatry Res. 2022 Feb;308:114349.
DOI: doi: 10.1016/j.psychres.2021.114349
IF: 11.225
Soler Artigas M, Sánchez-Mora C, Rovira P, Vilar-Ribó L, Ramos-Quiroga JA, Ribasés M
Mendelian randomization analysis for attention deficit/hyperactivity disorder: studying a broad range of exposures and outcomes.
Int J Epidemiol. 2022 Jun 12:dyac128.
DOI: doi: 10.1093/ije/dyac128
IF: 9.685
Eat2beNICE: Effects of Nutrition and Lifestyle on Impulsive, Compulsive, and Externalizing behaviors
Principal Investigator: J.A. Ramos-Quiroga; M. Ribases Haro
Agency: European Commission. Horizon 2020
Funding: 479,789.91€
Period: 2017 - 2022
PEARL: EU Patient- cEntric clinicAl tRial pLatform.
Principal Investigator: J.A. Ramos-Quiroga
Agency: European Commission. Horizon 2020-IMI2
Funding: 1,987,375€
Period: 2019 - 2022
SOCRATES: Self Conversation in Virtual Reality Embodiment to Enhance Healthier Lifestyles Among Obese People.
Principal Investigator: P. Lusilla; J.A. Ramos-Quiroga
Agency: European Commission. Horizon 2020
Funding: 397,875 €
Period: 2020 - 2023
DISCOvERIE: Development, dIagnosis and prevention of gender-related Somatic and mental COmorbiditiEs in iRrItable bowel syndrome in Europe.
Principal Investigator: J. A. Ramos-Quiroga
Agency: European Commission. Horizon 2020
Funding: 1,147,462.5 €
Period: 2020 - 2024
TIMESPAN: Management of chronic cardiometabolic disease and treatment discontinuity in adult ADHD patients (965381
Principal Investigator: J.A. Ramos-Quiroga
Agency: European Commission. Horizon 2020
Funding: 499,986€
Period: 2021-2025
Methods of treating attention deficit hyperactivity disorder using KDM1A inhibitors such as the compound unfidemstat
Priority Number: PCT/EP2020/057800
Priority Date: 20/03/2019
Applicants: Oryzon Genomics, S.A.
Methods of treating borderline personality disorder
Priority Number: PCT/EP2020/057803
Priority Date: 20/03/2019
Applicants: Oryzon Genomics, S.A.
Vafidemstat for use in treating autism spectrum disorders
Priority Number: PCT/EP2020/074602
Priority Date: 03/09/2020
Applicants: Oryzon Genomics, VHIR